share_log

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5

HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Lowers Price Target to $5

HC Wainwright & Co.重申对Pyxis Oncology的买入评级,目标价下调至5美元。
Benzinga ·  2024/12/20 23:55  · 评级/大行评级

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and lowers the price target from $7 to $5.

HC Wainwright & Co. 分析师Swayampakula Ramakanth重申对Pyxis Oncology(纳斯达克:PYXS)的买入评级,并将目标价格从7美元下调至5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发